Maze Therapeutics, Inc. reported $2.5M of revenue over the trailing twelve months. 6 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $2.5M (to Q2 2025). Net income: −$134M, trailing twelve months to Q2 2026. Free cash flow: −$107M, trailing twelve months to Q2 2026. EPS: −$2.47, trailing twelve months to Q2 2026.

MAZEMaze Therapeutics, Inc.

Healthcare

$27.11+18% 1Y

$27.11

$22.4052 weeks$51.83

MAZE as reported

Maze Therapeutics, Inc. reported $2.5M of revenue over the trailing twelve months. 6 reported series are charted on this page, each one as filed.

$2.5M

Revenue, trailing twelve months · to Q2 2025 · every figure below is as filed, with no scoring applied

Net income: −$134M
Net income · +11% year on year · trailing twelve months to Q2 2026
Free cash flow: −$107M
Free cash flow · +0.20% year on year · trailing twelve months to Q2 2026
EPS: −$2.47
EPS · −82% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for MAZE, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$2.5M	n/a	Q2 2025 · 4 quarters behind
Net income	−$134M	+11%	Q2 2026
EPS	−$2.47	−82%	Q2 2026
ROE	−34%	n/a	Q2 2026
ROA	−29%	n/a	Q2 2026
Free cash flow	−$107M	+0.20%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.